Treating osteogenesis imperfecta by inhibiting the PRC2 complex
Grant Project Details:
Awardee:
David Deyle, MD
Timeframe:
2020-2022
Location:
Mayo Clinic | Rochester, MN
Amount:
$250,000
Status:
In Process
Explore all RMM grants awarded since inception
Grant Description
The goal of this proposal is to develop a new strategy for skeletal regeneration in patients who have osteogenesis imperfecta (OI) or brittle bone disease using epigenetics regulators that alter gene expression. We have shown that inhibiting a epigenetic regulator, PCR2, increases bone formation in normal mice and will determine if this also occurs in OI mice. We will also investigate if a small molecule that inhibits the PRC2 complex can also increase bone formation in OI mice and cells from OI patients.
Grant Awardee Biography
